| Literature DB >> 32551551 |
Crystal J Wiersma1, Juan Manuel Belardinelli1, Charlotte Avanzi1, Shiva Kumar Angala1, Isobel Everall2,3, Bhanupriya Angala1, Edward Kendall1, Vinicius Calado Nogueira de Moura1, Deepshikha Verma1, Jeanne Benoit4, Karen P Brown2,5, Victoria Jones1, Kenneth C Malcolm6,7, Michael Strong4,7, Jerry A Nick6,7, R Andres Floto2,5, Julian Parkhill3,8, Diane J Ordway1, Rebecca M Davidson4, Michael R McNeil1, Mary Jackson1.
Abstract
Understanding the physiological processes underlying the ability of Mycobacterium abscessus to become a chronic pathogen of the cystic fibrosis (CF) lung is important to the development of prophylactic and therapeutic strategies to better control and treat pulmonary infections caused by these bacteria. Gene expression profiling of a diversity of M. abscessus complex isolates points to amino acids being significant sources of carbon and energy for M. abscessus in both CF sputum and synthetic CF medium and to the bacterium undergoing an important metabolic reprogramming in order to adapt to this particular nutritional environment. Cell envelope analyses conducted on the same representative isolates further revealed unexpected structural alterations in major cell surface glycolipids known as the glycopeptidolipids (GPLs). Besides showing an increase in triglycosylated forms of these lipids, CF sputum- and synthetic CF medium-grown isolates presented as yet unknown forms of GPLs representing as much as 10% to 20% of the total GPL content of the cells, in which the classical amino alcohol located at the carboxy terminal of the peptide, alaninol, is replaced with the branched-chain amino alcohol leucinol. Importantly, both these lipid changes were exacerbated by the presence of mucin in the culture medium. Collectively, our results reveal potential new drug targets against M. abscessus in the CF airway and point to mucin as an important host signal modulating the cell surface composition of this pathogen.Entities:
Keywords: Mycobacterium abscessus; branched-chain amino acids; cystic fibrosis; glycopeptidolipids; mucin; synthetic cystic fibrosis medium
Mesh:
Substances:
Year: 2020 PMID: 32551551 DOI: 10.1021/acsinfecdis.0c00214
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084